期刊文献+

安贝生坦研究进展 被引量:5

下载PDF
导出
摘要 安贝生坦是近年来开发研制的口服治疗重度肺动脉高压的一线药物,通过特异性拮抗内皮素ETA受体发挥治疗作用。该药肝脏不良反应较小,具有良好的应用前景,因而备受关注。该文就安贝生坦治疗肺动脉高压的研究进展进行综述。
作者 彭婕
出处 《医药导报》 CAS 2010年第5期640-643,共4页 Herald of Medicine
  • 相关文献

参考文献23

  • 1NEWMAN J H,FANBURG B L,ARCHER S L,et al.For the national heart,lung,and blood institute/office of rare diseases.Pulmonary arterial hypertension:future directions:report of a national heart,lung,and blood institute/office of rare diseases workshop[J].Circulation,2004,109:2947-2952.
  • 2FARBER H W,LOSCALZO J.Pulmonary arterial hyper-tension[J].N Engl J Med,2004,351(16):1655-1665.
  • 3HUMBERT M,SITBON O,SIMONNEAU G.Treatment of pulmonary arterial hypertension[J].N Engl J Med,2004,351(14):1425-1436.
  • 4杨宁,董俊军,刘克良.内皮素系统在肺动脉高压中的作用[J].国外医学(药学分册),2005,32(4):222-225. 被引量:2
  • 5SEO B,OEMAR B S,SIEBENMAN R,et al.Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels[J].Circulation,1994,89 (3):1203-1208.
  • 6荆志成.波生坦治疗肺动脉高压药理机制及其临床评价[J].中国医院用药评价与分析,2005,5(6):334-339. 被引量:17
  • 7PRIE S,STEWART D J,DUPUIS J.Endothelin areceptor block adeim provesnitricoxide mediatedvasodilation in monocrotaline induced pulmonary hypertension[J].Circulation,1998,97(21):2169-2174.
  • 8VATTER H,ZIMMERMANN M,JUNG C,et al.Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery[J].Clin Sci (Lond),2002,103(Suppl 48):408-413.
  • 9JUDY W M,CHENG B S.Ambrisentan for the management of pulmonary arterial hypertension[J].Clin The,2008,30(5):825-833.
  • 10JAMIE D C,SUSAN J K.Ambrisentan[J].Drugs,2008,68(15):2195-2204.

二级参考文献37

  • 1Schmitz-Spanke S, Schipke JD. Potential role of endothelin-1 and endothelin antagonist in cardiovascular diseases[ J]. Basic Res Cardiol,2000, 95(4) :290 - 298.
  • 2Seo B, Oemar BS, Siebenman R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels[J]. Circulation, 1994, 89(3): 1203 - 1208.
  • 3Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis[J]. Lancet,1993, 341(8860): 1550 - 1554.
  • 4Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease[ J ] ?Ann Intern Med, 1991, 114(6) :464 - 469.
  • 5Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension[ J].N Engl J Med, 1993, 328(24) :1732 - 1739.
  • 6Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-l[J]. Circulation, 1996, 94(7):1578 - 1584.
  • 7Ivy DD, Yanagisawa M, Gariepy CE, et al. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats [J].Am J Physiol Lung Cell Mol Physiol, 2002, 282(4) :L703 - L712.
  • 8Nishida M, Eshiro K, Okada Y, et al. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension[J]. J Cardiovasc Pharmacol , 2004, 44(2):187- 191.
  • 9Ergul A. Development of endothelin receptor antagonist as potential therapeutic agents[J]. Expert Opin Ther Patent, 2003, 13(1):33-44.
  • 10Prie S, Stewart DJ, Dupuis J. Endothelin A receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. [J]. Circulation, 1998, 97 ( 21 ): 2169 -2174.

共引文献17

同被引文献39

  • 1中国药典[S].2010年版.二部.附录ⅨJ.
  • 2胡昌勤,刘颖.药物残留溶剂的监控及其分析方法[J].药学学报,2007,42(12):1237-1242. 被引量:42
  • 3Romerdahl CA.Novel carboxylic acid derivatives, theirpreparation and use in treating cancer: WO, 9841206[P].1998-09-24.
  • 4Gmbn R.Ambrisentan in spezifischer kristalliner form: DE,202009009917[P].2010-03-18.
  • 5Kompelia A, Kasa S, Balina VS, et al.A process for thepreparation of highly pure ambrisentan: WO, 2011114338[P].2011-09-22.
  • 6钱 刚, 张文灵, 颜峰峰.一种2- 羟基丙酸类消旋物的拆分方法: 中国103086877A[P].2013-05-08.
  • 7Letairis (ambrisentan) Drug Information [EB]. [2014-05-05], <http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/02> 2081s0291bl.pdf.
  • 8JX20090317.安立生坦片国家药品标准[S].
  • 9崔福德,龙晓英.药剂学[M].第7版.北京:人民卫生出版 社,2011.
  • 10国家食品药品监督管理局药品审评中心.普通口服制剂溶 出度试验技术指导原则[EB]. 2012[2013-06-04], <http://www>. cde.org. cn/ zdyz.do?method=largePage?feid=177.

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部